Vaishali Pharma Limited (VAISHALI) - Total Assets
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) holds total assets worth Rs1.23 Billion INR (≈ $13.34 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check VAISHALI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Vaishali Pharma Limited - Total Assets Trend (2013–2026)
This chart illustrates how Vaishali Pharma Limited's total assets have evolved over time, based on quarterly financial data. Check Vaishali Pharma Limited cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Vaishali Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Vaishali Pharma Limited's total assets of Rs1.23 Billion consist of 91.6% current assets and 8.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.2% |
| Accounts Receivable | Rs507.73 Million | 41.2% |
| Inventory | Rs34.01 Million | 2.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2013–2026)
This chart illustrates how Vaishali Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VAISHALI market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaishali Pharma Limited's current assets represent 91.6% of total assets in 2026, a decrease from 98.0% in 2013.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2026, down from 3.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 41.2% of total assets.
Vaishali Pharma Limited Competitors by Total Assets
Key competitors of Vaishali Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Vaishali Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 2.61 | 1.37 |
| Quick Ratio | 2.27 | 2.49 | 1.36 |
| Cash Ratio | 0.00 | 0.05 | 0.00 |
| Working Capital | Rs646.64 Million | Rs644.31 Million | Rs220.33 Million |
Vaishali Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Vaishali Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | Rs1.23 Billion |
| Market Capitalization | $10.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaishali Pharma Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vaishali Pharma Limited's assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vaishali Pharma Limited (2013–2026)
The table below shows the annual total assets of Vaishali Pharma Limited from 2013 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs1.23 Billion ≈ $13.34 Million |
+12.33% |
| 2025-03-31 | Rs1.10 Billion ≈ $11.88 Million |
+37.38% |
| 2024-03-31 | Rs799.56 Million ≈ $8.65 Million |
+1.33% |
| 2023-03-31 | Rs789.07 Million ≈ $8.53 Million |
-3.33% |
| 2022-03-31 | Rs816.24 Million ≈ $8.83 Million |
-5.22% |
| 2021-03-31 | Rs861.23 Million ≈ $9.31 Million |
+30.09% |
| 2020-03-31 | Rs662.04 Million ≈ $7.16 Million |
-3.70% |
| 2019-03-31 | Rs687.51 Million ≈ $7.44 Million |
+6.88% |
| 2018-03-31 | Rs643.23 Million ≈ $6.96 Million |
+44.07% |
| 2017-03-31 | Rs446.49 Million ≈ $4.83 Million |
-10.29% |
| 2016-03-31 | Rs497.73 Million ≈ $5.38 Million |
+8.69% |
| 2015-03-31 | Rs457.95 Million ≈ $4.95 Million |
-14.29% |
| 2014-03-31 | Rs534.30 Million ≈ $5.78 Million |
+9.98% |
| 2013-03-31 | Rs485.82 Million ≈ $5.25 Million |
-- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more